

# INFECTION CONTROL



## EDITORIAL

### **Reimbursement for Nosocomial Infections Under the Prospective Payment Plan: The Future or Decline of Infection Control?**

Bruce F. Farber, MD

## ORIGINAL ARTICLES

### ***Serratia marcescens* Contamination of Antiseptic Soap Containing Triclosan: Implications for Nosocomial Infection**

M. Anita Barry, MD; Donald E. Craven, MD; Theresa A. Goularte, BS; Deborah A. Lichtenberg, RN

### **Effect of Antiseptic Agents on Skin Flora of the Perineum of Men with Spinal Cord Injury**

John Z. Montgomerie, MD; Donna S. Gilmore, RN, BS; Irene E. Graham, RN; Donald S. Schick, BS; Enes M. Jimenez, RN, MPH

### **Permeability of the Thermometer Sheath When Taking Oral Temperatures**

Donald J. Soltero, DDS, MSD; Earl E. Sommers, DDS, MSD; Edmond T. Truelove, DDS, MSD

### **Risks and Benefits of Vaccinations**

Gerhard Wiedermann, MD; Franz Ambrosch, MD; Herwig Kollaritsch, MD; Matthias Kundi, PhD

### **Product Commentary: Developing Criteria for the Selection of Packaging Material**

Phyllis M. Smith, RN

### **Topics in Clinical Microbiology: Detection of Bacteremia and Fungemia—Microscopic Examination of Peripheral Blood Smears**

Barney S. Graham, MD



## WHAT'S THE BEST HANDWASH/SCRUB? HANDS UP OR HANDS DOWN IT'S

# HIBICLENS<sup>®</sup>

(CHLORHEXIDINE GLUCONATE)

It is well established that handwashing is the most important single procedure in preventing transmission of hospital-acquired infections. HIBICLENS, the only proven antiseptic/antimicrobial, is the best agent available for both personnel handwashing and surgical scrubbing. HIBICLENS

provides the most immediate and prolonged protection against infection, with the best bactericidal "kill rate." And to encourage skin cleansing among hospital personnel, HIBICLENS offers cosmetic acceptability coupled with an excellent safety profile. Gentle to the skin, HIBICLENS is virtually

nonirritating and nonsensitizing, with a low potential for toxicity.

Available as both a liquid and impregnated in a disposable Sponge/Brush, HIBICLENS remains the single most effective antiseptic/antimicrobial skin cleanser for use throughout the hospital.

**THE BEST ANTISEPTIC/ANTIMICROBIAL SKIN CLEANSER**



# INFECTION CONTROL

## Table of Contents

### Editorial

- Reimbursement for Nosocomial Infections Under the Prospective Payment Plan: The Future or Decline of Infection Control?** 425  
 Bruce F. Farber, MD

### Original Articles

- Serratia marcescens* Contamination of Antiseptic Soap Containing Triclosan: Implications for Nosocomial Infection** 427  
 M. Anita Barry, MD; Donald E. Craven, MD, Theresa A. Goularte, BS; Deborah A. Lichtenberg, RN
- Effect of Antiseptic Agents on Skin Flora of the Perineum of Men With Spinal Cord Injury** 431  
 John Z. Montgomerie, MD; Donna S. Gilmore, RN, BS; Irene E. Graham, RN; Donald S. Schick, BS; Enes M. Jimenez, RN, MPH
- Permeability of the Thermometer Sheath When Taking Oral Temperatures** 435  
 Donald J. Soltero, DDS, MSD; Earl E. Sommers, DDS, MSD; Edmond T. Truelove, DDS, MSD
- Risks and Benefits of Vaccinations** 438  
 Gerhard Wiedermann, MD; Franz Ambrosch, MD; Herwig Kollaritsch, MD; Matthias Kundi, PhD
- Product Commentary: Developing Criteria for the Selection of Packaging Materials** 445  
 Phyllis M. Smith, RN
- Topics in Clinical Microbiology: Detection of Bacteremia and Fungemia—Microscopic Examination of Peripheral Blood Smears** 448  
 Barney S. Graham, MD

### Departments

- |                                |     |                               |     |
|--------------------------------|-----|-------------------------------|-----|
| <b>Letters to the Editor</b>   | 419 | <b>Calendar of Events</b>     | 457 |
| <b>Information for Authors</b> | 453 | <b>Classified Marketplace</b> | 460 |
| <b>Book Reviews</b>            | 455 |                               |     |

---

The ideas and opinions expressed by contributing authors do not necessarily reflect those of the editors or publisher.

---

**Publisher:** *Infection Control* (ISSN-0195-9417) is published monthly by SLACK Incorporated, 6900 Grove Road, Thorofare, New Jersey 08086. Telephone: Thorofare (609) 848-1000.

**Copyright 1984:** All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

**Subscriptions:** Subscription requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Scope Incorporated, 11-11, Shoto 2-chrome, Shibuya-Ku, Tokyo 150, Japan. Annual subscription price is: Individual: One year—\$35.00; Two years—\$50.00; Three years—\$65.00. Institutional: One year—\$50.00; Two years—\$65.00; Three years—\$80.00. All subscriptions, without exception, will start with the first issue published after the order is received. Back copies are available, but must be purchased separately. Cost per individual copy is \$5.00. Foreign subscribers add \$15.00 to regular rate: foreign orders, \$6.00.

**Change of address:** Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Second-class postage is paid at Thorofare, New Jersey 08086. Publisher requests Form 3547 for address correction changes.

As of Volume 1, Number 1, *Infection Control* is listed in *Index Medicus*, *Current Contents—Clinical Practice*, *Hospital Literature Index*, and *Cumulative Index to Nursing and Allied Health Literature*.

# INFECTION CONTROL.

# reprints

## REPRINT ORDER

JOURNAL \_\_\_\_\_ ISSUE \_\_\_\_\_

AUTHOR \_\_\_\_\_ TITLE OF ARTICLE \_\_\_\_\_



Page Nos. \_\_\_\_\_ Quantity \_\_\_\_\_

Minimum order 100 - minimum price based on 4 pages.  
 For orders over 1,000 please write or call for quotation.  
 Postage and/or Freight extra

| Pages                      | 1-4    | 5-8    | 9-12   | 13-16  | 17-20  |
|----------------------------|--------|--------|--------|--------|--------|
| 100 Copies                 | 80.00  | 140.75 | 214.25 | 281.50 | 365.75 |
| 200 Copies                 | 90.25  | 169.25 | 256.25 | 336.00 | 437.00 |
| 300 Copies                 | 108.00 | 197.50 | 298.00 | 390.25 | 508.00 |
| 400 Copies                 | 125.50 | 225.50 | 339.50 | 444.25 | 578.75 |
| 500 Copies                 | 142.75 | 253.25 | 380.75 | 498.00 | 649.25 |
| Add'l 100s up to 1,000 add | 17.00  | 27.50  | 41.00  | 53.50  | 70.25  |

Bill Me       Check Enclosed (Remit in U.S. Dollars.  
 Make checks payable to "SLACK Incorporated.")

Ordered by: \_\_\_\_\_  
 Name \_\_\_\_\_  
 Address \_\_\_\_\_  
 City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Charge my VISA or MasterCard    
 Account Number  
                 
 Bank ID # (MC Only—Located above your name, lower left-hand corner of card.)

Expiration Date: \_\_\_\_\_

# INFECTION CONTROL / Editorial Board

## EDITOR

**Richard P. Wenzel, MD**  
Charlottesville, Virginia

## SENIOR ASSOCIATE EDITOR

**William Schaffner, MD**  
Nashville, Tennessee

## ASSOCIATE EDITORS

**Sue Crow, RN, MSN**  
Shreveport, Louisiana

**John E. McGowan, Jr., MD**  
Atlanta, Georgia

**Dennis G. Maki, MD**  
Madison, Wisconsin



SLACK Incorporated  
6900 Grove Road  
Thorofare, New Jersey 08086

## Publisher

Richard N. Roash

## Managing Editor

Donna Carpenter

## Consulting Editor

Eric Baloff

## Assistant Editor

Linda L. Jones

## Circulation Manager

Kevin J. Fenton

## Advertising Manager

Melissa Warner

## Advertising

## Sales Representative

Wayne McCourt

## Classified

## Advertising Representative

Harriet E. Hampton

## EDITORIAL

### ADVISORY BOARD

Robert C. Aber, MD  
Hershey, Pennsylvania

Charles S. Bryan, MD  
Columbia, South Carolina

John P. Burke, MD  
Salt Lake City, Utah

Marie B. Coyle, PhD  
Seattle, Washington

Burke A. Cunha, MD  
Mineola, New York

Richard E. Dixon, MD  
Trenton, New Jersey

Harvey A. Elder, MD  
Loma Linda, California

Bruce Farber, MD  
Pittsburgh, Pennsylvania

Peter C. Fuchs, MD, PhD  
Portland, Oregon

Richard A. Garibaldi, MD  
Farmington, Connecticut

Donald A. Goldmann, MD  
Boston, Massachusetts

Dieter H.M. Gröschel, MD  
Charlottesville, Virginia

Peter A. Gross, MD  
Hackensack, New Jersey

Karen Hadley, RN, MPH  
New Orleans, Louisiana

David K. Henderson, MD  
Bethesda, Maryland

Peter N.R. Heseltine, MD  
Los Angeles, California

Cyrus C. Hopkins, MD  
Boston, Massachusetts

Allen B. Kaiser, MD  
Nashville, Tennessee

Harold Laufman, MD, PhD  
New York, New York

William J. Ledger, MD  
New York, New York

Barbara McArthur, RN, PhD  
Detroit, Michigan

Rob Roy MacGregor, MD  
Philadelphia, Pennsylvania

C. Glen Mayhall, MD  
Richmond, Virginia

Ronald Lee Nichols, MD  
New Orleans, Louisiana

Harry C. Nottebart, Jr., JD, MD  
Richmond, Virginia

James E. Peacock, Jr., MD  
Winston-Salem, North Carolina

Frank S. Rhame, MD  
Minneapolis, Minnesota

William A. Rutala, PhD, MPH  
Chapel Hill, North Carolina

William E. Scheckler, MD  
Madison, Wisconsin

Robert J. Shannon, MSPH  
Boston, Massachusetts

Walter E. Stamm, MD  
Seattle, Washington

Charles W. Stratton, MD  
Nashville, Tennessee

Timothy R. Townsend, MD  
Baltimore, Maryland

William M. Valenti, MD  
Rochester, New York

James Veazey, MD  
Albany, New York

Kathy J. Wydra, RN  
Geneva, New York

## FOREIGN ADVISORY BOARD

Graham Ayliffe, MD, FRC Path.  
Birmingham, England

Professor G. Berencsi  
Szeged, Hungary

Professor Jaap Dankert  
Groningen, Netherlands

Professor Dr. F. Daschner  
Freiburg, West Germany

Lars O. Kallings, MD  
Stockholm, Sweden

Professor W.B. Kędzia  
Sieroca, Poland

Professor A.P. Krasilnikow  
Minsk, USSR

Professor Dr. W. Marget  
Munich, West Germany

Bertil Nyström, MD  
Huddinge, Sweden

Ian Phillips, MA, MD, MRC Path.  
London, England

Samuel Ponce de Leon, MD  
Mexico City, Mexico

Hans Reber, MD  
Basel, Switzerland

Professor Gerald Reybrouck  
Leuven, Belgium

Manfred L. Rotter, MD, DipBact  
Vienna, Austria

Theodore Sacks, MD  
Jerusalem, Israel

Dr. Bernhard M. Thimm  
Federal Republic of Germany

Professor Dr. med. H.P. Werner  
Mainz, West Germany

Professor Dr. W. Weuffen

Greifswald, German Democratic Republic



**MERIEUX.**  
**BECAUSE RABIES IS TOO SERIOUS**  
**TO TAKE CHANCES WITH ANYTHING BUT**  
**THE SAFEST, MOST EFFECTIVE**  
**AND COMPLETE RABIES PROTECTION**  
**YOU CAN FIND.**

**R**abies—always dangerous, usually deadly. You want Merieux, the U.S. leader in rabies therapy. Only Merieux has IMOVAX RABIES Rabies Vaccine and new IMO GAM RABIES Rabies Immune Globulin (Human), the only complete post-exposure therapy program available from one company. And it's therapy that's 100% effective and safe. After all, IMOVAX RABIES alone has been proven in over 2,500,000 doses worldwide. Merieux also offers emergency delivery, pre-exposure treatment, and a complete public information service ready to answer your questions about rabies. So remember Merieux, IMOVAX RABIES and IMO GAM RABIES in rabies therapy. Because infection this deadly demands protection this complete.

**IMOVAX® RABIES**  
RABIES VACCINE  
(HUMAN DIPLOID CELL)



**IMO GAM® RABIES**  
RABIES IMMUNE GLOBULIN  
(HUMAN) U.S.P.



 **MERIEUX INSTITUTE, INC.**

1200 N. W. 78th Avenue, Suite 109  
Miami, Florida 33126  
24 hours a day, 7 days a week,  
call toll-free 800-327-2842.  
In Alaska, Florida and Hawaii,  
call collect (305) 593-9577.

# RABIES IMMUNE GLOBULIN (HUMAN), U.S.P. **IMOGAM® RABIES**

**DESCRIPTION:** Rabies Immune Globulin (Human) IMOGAM® RABIES is a sterile solution of antirabies immunoglobulin (10-18% protein) for intramuscular administration. It is prepared by cold alcohol fractionation from pooled venous plasma of individuals immunized with Rabies Vaccine prepared from human diploid cells (HDCV). The product is stabilized with 0.3 M glycine and contains 1:10,000 sodium ethylmercurithiosalicylate (thimerosal) as a preservative. The globulin solution has a pH of  $6.8 \pm 0.4$  adjusted with sodium hydroxide or hydrochloric acid. The product is standardized against the U.S. Standard Rabies Immune Globulin. The U.S. unit of potency is equivalent to the International Unit (I.U.) for rabies antibody. The product is prepared from units of human plasma that have been tested and found negative for hepatitis B surface antigen (HBsAg) by FDA-required tests.

**CONTRAINDICATIONS:** Rabies Immune Globulin (Human) should not be administered in repeated doses once vaccine treatment has been initiated. Repeating the dose may interfere with maximum active immunity expected from the vaccine.

**WARNINGS:** Rabies Immune Globulin (Human) should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immune globulin preparations or those individuals allergic to thimerosal.

Persons with specific IgA deficiency have increased potential for developing antibodies to

IgA and could have anaphylactic reactions to subsequent administration of blood products containing IgA.<sup>1,2</sup>

**PRECAUTIONS:** *General*—Rabies Immune Globulin (Human) should not be administered intravenously because of the potential for serious reactions. Injection should be made intramuscularly and care should be taken to draw back on the plunger of the syringe before injection in order to be certain that the needle is not in a blood vessel. Although systemic reactions to immunoglobulin preparations are rare, epinephrine should be available for treatment of acute anaphylactoid systems. As with all preparations given intramuscularly, bleeding complications may be encountered in patients with bleeding disorders.

*Drug Interactions*—Live virus vaccines such as measles vaccines should not be given close to the time of Rabies Immune Globulin (Human) administration because antibodies in the globulin preparation may interfere with the immune response to the vaccination. Immunization with live vaccines should not be given within three months after Rabies Immune Globulin (Human) administration.

*Pregnancy Category C*—Animal reproduction studies have not been conducted with Rabies Immune Globulin (Human). It is also not known whether RIG(H) can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. RIG(H) should be given to a pregnant woman only if clearly needed.

**ADVERSE REACTIONS:** Local or mild systemic adverse reactions to the globulin after intramuscular injections are uncommon<sup>3,4</sup> and may be treated symptomatically. Local tenderness, soreness or stiffness of the muscles may occur at the injection site and may persist for several hours after injection. Urticaria and angioedema may occur. Anaphylactic reactions, although rare, have been reported following injection of human immune globulin preparations.

## REFERENCES:

1. Fudenberg H.H. Sensitization to immunoglobulins and hazards of gamma globulin therapy, pp 211-220 in Merler E., Editor, Immunoglobulins: biologic aspects and clinical uses. National Academy of Sciences, Wash., D.C., 1970.
2. Pineda A.A. and Taswell H.F. Transfusion reactions associated with anti-IgA antibodies: Report of four cases and review of the literature. *Transfusion* 15:10-15 (1975).
3. Janeway C.A., Rosen F.S. The gamma globulins. IV. Therapeutic uses of gamma globulins. *N Engl J Med* 275:826-831 (1966).
4. Kjellman H. Adverse reactions to human immune serum globulin in Sweden (1969-1978) pp 143-150. Immunoglobulins: Characteristics and uses of intravenous preparations. Alving B.M. and Finlayson J.S., Editors. U.S. Dept. Health & Human Services, DHHS Publ. No. (FDA) 80-9005, Wash., D.C., 1980.

Issued January, 1984

# RABIES VACCINE (HUMAN DIPLOID CELL) **IMOVAX® RABIES**

Wistar Rabies Virus Strain PM-1503-3M Grown in Human Diploid Cell Cultures

**DESCRIPTION:** The IMOVAX® RABIES Vaccine produced by Institut Merieux is a sterile, stable freeze-dried suspension of rabies virus prepared from strain PM-1503-3M obtained from the Wistar Institute, Philadelphia, Pennsylvania. The virus is harvested from infected human diploid cells, MRC-5 strain, concentrated by ultrafiltration and is inactivated by beta propiolactone. One dose of reconstituted vaccine contains less than 100 mg human albumin, less than 150 µg neomycin sulfate and 20 µg of phenol red indicator.

The vaccine contains no preservative or stabilizer. It should be used immediately after reconstitution.

The potency of Merieux IMOVAX® RABIES Vaccine is equal to or greater than 2.5 International Units of rabies antigen.

**CONTRAINDICATIONS:** For post-exposure treatment, there are no known specific contraindications to the use of Merieux IMOVAX® RABIES Vaccine. In cases of pre-exposure immunization, there are no known specific contraindications other than situations such as developing febrile illness, etc.

**WARNINGS:** Local or mild systemic adverse reactions to the vaccine are infrequent; they do not contraindicate continuing immunization and may be treated symptomatically. Neuroparalytic reactions such as encephalomyelitis, transverse myelitis and other central neuropathies have not been reported in recipients of vaccine produced in human diploid cell cultures. One case of Guillain-Barré syndrome temporally associated with rabies immunization has been reported.<sup>1</sup> It was followed by complete recovery. No cause-effect relationship was established. Should a neurological complication develop, vaccine treatment should be discontinued. Any serious reactions should

be immediately reported to the State Health Department or the Viral Disease Division, Bureau of Epidemiology, Centers for Disease Control, Atlanta, Georgia (telephone (404) 329-3696).

**PRECAUTIONS:** Epinephrine should be available for immediate use should an anaphylactoid reaction occur.

*Drug Interactions*—Corticosteroids and immunosuppressive agents may interfere with the development of active immunity and predispose the patient to developing rabies. They should not be administered during post-exposure therapy unless essential for the treatment of other serious conditions. If rabies post-exposure therapy is administered to persons receiving steroids or immunosuppressive therapy, it is especially important that serum be tested for rabies antibody to ensure that an adequate response has developed.

*Usage in Pregnancy*—Pregnancy is not a contraindication to rabies post-exposure therapy. Based on limited data, there have been no fetal abnormalities associated with rabies vaccination. If there is substantial risk of rabies exposure, pre-exposure treatment may also be indicated during pregnancy.

**ADVERSE REACTIONS:** Clinical experience with Merieux IMOVAX® RABIES Vaccine has resulted in a low incidence of adverse reactions when administered by the recommended route of injection. Local reactions consist of swelling, erythema, induration and slight ache. Their incidence has ranged from approximately 3% to 15%.<sup>2,3,4,5</sup> Allergic reactions to Merieux rabies diploid cell vaccine are rare. In the few cases reported,<sup>1</sup> which ranged in severity from hives to anaphylactic shock, it was not necessary to discontinue the post-exposure prophylaxis regimen. Mild local or systemic reactions can be treated with anti-inflammatory, antipyretic agents, e.g., aspirin

and antihistamines. If an anaphylactic reaction should occur, epinephrine is indicated.

## REFERENCES:

1. MMWR, Vol. 29, No. 50, pp 609-610, December 19, 1980. U.S. Department of Health & Human Services (CDC).
2. Aoki F.Y., Tyrrell D.A.J., Hill L.E. Immunogenicity and acceptability of a human diploid cell culture rabies vaccine in volunteers. *Lancet* 1:660-662, March 22, 1975.
3. Ajjan N., Soulebot J.P., Stellmann C., et al. Resultats de la vaccination antirabique préventive par le vaccin inactivé concentré souche rabies PM/W 138-1503-3M cultivée sur cellules diploïdes humaines. *Develop Biol Stand* 40:89-100. S. Karger, Basel, 1978.
4. Costy-Berger F. Vaccination antirabique préventive par du vaccin préparé sur cellules diploïdes humaines. *Develop Biol Stand* 40:101-104. S. Karger, Basel, 1978.
5. Kuwert E. K., Marcus I., Wernier J., et al. Some experiences with human diploid cell strain (HDCS) rabies vaccine in pre- and post-exposure vaccinated humans. *Develop Biol Stand* 40:79-88. S. Karger, Basel, 1978.

Revised November, 1981.

Distributed by:  
MERIEUX INSTITUTE, INC.  
Miami, Florida 33126  
800-327-2842, (305) 593-9577

Manufactured by:  
INSTITUT MERIEUX  
Lyon-France  
U.S. License No. 384

©1984 Merieux Institute, Inc.

 MERIEUX INSTITUTE USA